Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Soft Tissue Sarcoma: early-phase trial registry
22 of 56 indexed Soft Tissue Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #252 of 28,707 conditions by registered trial count.
56 US clinical trials · 22 currently recruiting · #252 of 28,707 conditions by registered trial count
Soft Tissue Sarcoma: 56 US clinical trials tracked, 22 recruiting.
Soft Tissue Sarcoma is the subject of 56 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition soft-tissue-sarcoma
OPEN 22 | RECR 39% | LATE 2 | EARLY 43 | RANK #252 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Eye Diseases (39% recruiting · 28 trials)
Soft Tissue Sarcoma lists 22 open slots (39% of 56 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Soft Tissue Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Soft Tissue Sarcoma recruits in line with its size-band peers.
22 of 56 indexed trials (39.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Soft Tissue Sarcoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 4 of 56 trials (7.1%). 42 distinct sponsors appear on at least one study for this condition label.
-
Most Soft Tissue Sarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 56 trials that report a genuine target (sentinel values excluded). 47 of those (83.9%) plan for fewer than 100 participants.
-
Soft Tissue Sarcoma research is mostly interventional.
52 interventional and 4 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
56 total, page 1 of 2
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Advenchen Laboratories
NCT03016819
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Polaris Group
NCT05712694
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences
NCT04969835
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
NCT04577014
5-Day Preoperative Radiation for Soft Tissue Sarcoma
Stanford University
NCT06087861
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
NCT07064018
Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
Memorial Sloan Kettering Cancer Center
NCT06129903
Genomic Risk in Retroperitoneal Sarcoma
Fox Chase Cancer Center
NCT06436846
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
M.D. Anderson Cancer Center
NCT07049848
Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma
Mayo Clinic
NCT06409013
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
NCT04040205
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics
NCT06566092
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
QBiotics Group Limited
NCT05755113
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
Medical University of South Carolina
NCT06905132
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
M.D. Anderson Cancer Center
NCT05621668
Pre-operative Hypofractionated Proton Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05917301
Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma
Mayo Clinic
NCT05526417
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
University of Wisconsin, Madison
NCT05109494
68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
Ohio State University Comprehensive Cancer Center
NCT06500065
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
NCT04995003
Exercise and Soft Tissue Sarcoma
Duke University
NCT04921917
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
NCT05264974
Surveillance AFter Extremity Tumor surgerY
McMaster University
NCT03944798
Radiation Therapy to Treat Musculoskeletal Tumors
St. Jude Children's Research Hospital
NCT00186992
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs
Memorial Sloan Kettering Cancer Center
NCT04288375
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center
NCT04165330
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
University of Wisconsin, Madison
NCT03972930
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
NCT03114527
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Immunophotonics
NCT05688280
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
NCT02923778
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Eli Lilly and Company
NCT03899792
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
University of Iowa
NCT04634227
APX005M and Doxorubicin in Advanced Sarcoma
Alexander Z. Wei, MD
NCT03719430
Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Fox Chase Cancer Center
NCT04055753
Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma
Medical University of South Carolina
NCT05776667
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT05886634
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
John Rieth
NCT04599062
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Washington University School of Medicine
NCT05813327
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
John Rieth
NCT06660810
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
Philogen S.p.A.
NCT04032964
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Bristol-Myers Squibb
NCT00633789
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Eli Lilly and Company
NCT02659020
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma
NCT02632448
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
NCT02301039
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
NCT03449901
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Mundipharma Research Limited
NCT03345485
Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas
Children's Oncology Group
NCT01802125
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Mohammed M Milhem
NCT01106872
Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Kristen Ganjoo
NCT04118166
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 20 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Soft Tissue Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Soft Tissue Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Soft Tissue Sarcoma page
56 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 22 Soft Tissue Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Soft Tissue Sarcoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Soft Tissue Sarcoma condition card totals 56 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.